Therapeutic Nuclear Medicine Market Size, Share, Growth, and Industry Analysis, By Type (Radium-223, Iodine-131, Leutitium-177, Yttrium-90, Samarium-153, Strontium-89, Rhenium-188+Rhenium-186, Erbium- 169, Phosphorous-32, Others), By Application (Hospitals, Ambulatory Surgical Centers, Cancer Research Institutes), Regional Insights and Forecast to 2035

Therapeutic Nuclear Medicine Market Overview

The global Therapeutic Nuclear Medicine Market size estimated at USD 6918.94 million in 2026 and is projected to reach USD 13765.54 million by 2035, growing at a CAGR of 7.95% from 2026 to 2035.

The therapeutic nuclear medicine market is expanding rapidly due to the increasing prevalence of cancer, cardiovascular disorders, and neurological diseases worldwide. More than 20 million new cancer cases were diagnosed globally during 2024, while approximately 38% of oncology centers integrated radionuclide therapies into treatment protocols. Therapeutic nuclear medicine procedures exceeded 52 million annually across hospitals and specialty cancer centers. Lutetium-177 therapies accounted for nearly 29% of therapeutic radiopharmaceutical usage because of high adoption in neuroendocrine tumor and prostate cancer treatment. Around 61% of nuclear medicine facilities upgraded isotope handling systems during 2025 to improve treatment precision, radiation safety, and patient throughput efficiency.

The United States remains a dominant market for therapeutic nuclear medicine because more than 2 million new cancer cases were recorded during 2025. Approximately 46% of oncology hospitals across the country adopted advanced radioligand therapy platforms for metastatic cancer treatment. More than 320 licensed nuclear medicine centers in the United States expanded therapeutic isotope administration capacity during 2024. Lutetium-177 and Yttrium-90 therapies represented nearly 41% of radionuclide therapy procedures nationwide. Government-backed isotope production initiatives increased domestic isotope supply by 24%, while around 37% of cancer treatment institutions integrated AI-assisted imaging systems for precision therapeutic planning and radiation dose optimization.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 67% of oncology treatment centers increased radiopharmaceutical adoption, while 54% of advanced cancer patients received targeted radionuclide therapies during 2025.
• Major Market Restraint: Around 39% of healthcare providers reported isotope supply shortages, while radioactive material transportation delays increased by 21% during 2024.
• Emerging Trends: Nearly 48% of nuclear medicine facilities adopted theranostic treatment approaches, while 33% integrated AI-supported radiotherapy planning systems during 2025.
• Regional Leadership: North America accounted for approximately 41% market share during 2025, while Europe represented 29% because radiopharmaceutical infrastructure expanded significantly.
• Competitive Landscape: The top five companies controlled nearly 58% market share, while 44% focused on lutetium-based therapeutic isotope manufacturing capacity.
• Market Segmentation: Lutetium-177 therapies accounted for approximately 29% market share, while hospitals contributed nearly 63% of total therapeutic nuclear medicine demand.
• Recent Development: Around 36% of manufacturers expanded isotope production facilities during 2025, while 31% launched targeted alpha therapy development programs.

Therapeutic Nuclear Medicine Market Latest Trends

The therapeutic nuclear medicine market is witnessing rapid technological advancements because cancer incidence and precision medicine adoption continue increasing globally. More than 52 million therapeutic nuclear medicine procedures were performed during 2025, while approximately 48% of oncology facilities integrated theranostic treatment approaches combining diagnostics and targeted radionuclide therapy. Lutetium-177 therapies emerged as a dominant market trend because treatment adoption for metastatic prostate cancer increased by 34% during 2024. Around 29% of all therapeutic radiopharmaceutical procedures globally involved lutetium-based isotopes because of improved tumor-targeting efficiency and reduced damage to healthy tissues. Yttrium-90 therapies also gained traction, while liver cancer treatment procedures increased by 22%.

AI-supported treatment planning systems became another major trend during 2025. Approximately 37% of nuclear medicine centers integrated AI-driven imaging and radiation dose optimization platforms to improve treatment precision. Automated isotope dispensing systems additionally reduced radiopharmaceutical preparation errors by 19%. Hospitals and research institutions also expanded investments in domestic isotope production. Around 26% of therapeutic isotope manufacturers upgraded cyclotron and reactor-based isotope generation facilities during 2025 to improve supply stability and reduce dependency on imported radioactive materials.

Therapeutic Nuclear Medicine Market Dynamics

DRIVER

"Rising prevalence of cancer and chronic diseases."

The increasing prevalence of cancer and chronic diseases remains the primary growth driver for the therapeutic nuclear medicine market. More than 20 million new cancer diagnoses were reported globally during 2024, while approximately 10 million cancer-related deaths increased demand for advanced targeted therapies. Around 61% of oncology hospitals adopted therapeutic radiopharmaceutical treatments because radionuclide therapies improved tumor-targeting accuracy and minimized systemic toxicity. Prostate cancer, thyroid cancer, and neuroendocrine tumors significantly contributed to market expansion. Approximately 29% of metastatic prostate cancer patients received lutetium-177 therapies during 2025 because treatment response rates improved substantially. Cardiovascular and neurological disease applications also expanded, while around 18% of nuclear medicine facilities increased isotope utilization for non-oncology therapies. Government healthcare investments and precision medicine initiatives further accelerated therapeutic nuclear medicine adoption globally.

RESTRAINT

"Limited isotope availability and supply chain disruptions."

Limited isotope availability and supply chain disruptions continue restraining therapeutic nuclear medicine market expansion. Approximately 39% of hospitals and oncology centers reported periodic shortages of key therapeutic isotopes during 2024 because reactor maintenance and transportation regulations affected supply continuity. Radioactive isotope transportation delays increased by 21%, especially across international healthcare distribution networks. Lutetium-177 and Yttrium-90 production facilities remained concentrated in limited geographic regions, while approximately 28% of healthcare providers experienced scheduling delays for radionuclide therapies due to isotope allocation limitations. Regulatory compliance requirements additionally increased operational costs for radiopharmaceutical handling and storage infrastructure. Around 24% of smaller hospitals delayed nuclear medicine department expansion because radiation shielding systems and isotope processing equipment required substantial investment.

OPPORTUNITY

"Expansion of targeted radioligand therapy and theranostics."

The rapid expansion of targeted radioligand therapy and theranostic medicine creates major opportunities for the therapeutic nuclear medicine market. Approximately 48% of advanced oncology treatment centers adopted theranostic approaches during 2025 because combined diagnostic and therapeutic procedures improved personalized treatment outcomes. Lutetium-177 radioligand therapies demonstrated strong clinical adoption, while treatment procedures increased by 34% globally during 2024. Around 31% of pharmaceutical research organizations expanded development programs for alpha-emitting isotopes and next-generation targeted radionuclide therapies. Emerging economies also created opportunities because cancer screening and nuclear medicine infrastructure investments increased significantly. Research institutes further accelerated innovation in targeted isotope delivery systems. Approximately 26% of oncology clinical trials initiated during 2025 focused on therapeutic radiopharmaceuticals for metastatic cancer treatment. Artificial intelligence integration and robotic isotope dispensing systems additionally improved operational efficiency across nuclear medicine facilities.

CHALLENGE

"Radiation safety compliance and skilled workforce shortages."

Radiation safety compliance and shortages of skilled nuclear medicine professionals remain major challenges for the therapeutic nuclear medicine market. Approximately 33% of healthcare facilities reported shortages of trained radiopharmacists and nuclear medicine technologists during 2025. Strict radiation handling regulations increased operational complexity for hospitals and isotope manufacturers. Treatment precision requirements created additional operational challenges. Approximately 21% of nuclear medicine facilities upgraded dosimetry systems during 2025 to ensure accurate radiation dose administration and minimize healthy tissue exposure during therapy procedures.

Therapeutic Nuclear Medicine Market Segmentation

Download FREE Sample to learn more about this report.

The therapeutic nuclear medicine market is segmented by isotope type and application based on treatment effectiveness, disease targeting capabilities, and healthcare infrastructure requirements. Lutetium-177 accounted for approximately 29% market share during 2025 because of widespread adoption in neuroendocrine and prostate cancer treatment. Iodine-131 represented nearly 21% share due to strong thyroid cancer therapy demand. By application, hospitals dominated with approximately 63% market share because large oncology centers performed high volumes of radionuclide procedures. Cancer research institutes accounted for nearly 19% of total market demand due to increasing radiopharmaceutical clinical trials and isotope therapy development programs.

BY TYPE

Radium-223: Radium-223 accounted for approximately 11% market share during 2025 because of strong adoption in metastatic bone cancer treatment. Around 43% of advanced prostate cancer patients with bone metastases received Radium-223 therapy because targeted alpha radiation reduced skeletal complications significantly. North America represented nearly 39% of Radium-223 procedures due to advanced oncology treatment infrastructure. Hospitals expanded Radium-223 treatment programs during 2024, while procedure volumes increased by 18%. Approximately 26% of oncology centers integrated AI-supported bone metastasis imaging to optimize radionuclide therapy planning. Europe also demonstrated strong demand because bone-targeted cancer therapies gained wider regulatory approvals.

Iodine-131: Iodine-131 represented approximately 21% market share during 2025 because thyroid cancer and hyperthyroidism treatment volumes remained high globally. More than 1.1 million Iodine-131 therapeutic procedures were performed annually, while approximately 58% of thyroid cancer patients received radioactive iodine therapy following surgical intervention. Asia-Pacific accounted for nearly 34% of global Iodine-131 demand because thyroid disorder prevalence increased significantly. Around 41% of nuclear medicine departments upgraded isotope storage and administration systems during 2025 to improve radiation handling efficiency. Research institutions also expanded development of low-dose Iodine-131 treatment protocols to minimize side effects.

Leutitium-177: Lutetium-177 dominated the therapeutic nuclear medicine market with approximately 29% share during 2025 because radioligand therapies for neuroendocrine tumors and prostate cancer expanded rapidly. Around 52% of advanced radiopharmaceutical treatment centers integrated Lutetium-177 therapy platforms because treatment precision improved tumor-targeting performance significantly. Global treatment procedures increased by 34% during 2024 because metastatic prostate cancer incidence continued rising. Approximately 47% of oncology clinical trials involving therapeutic isotopes focused on Lutetium-177 applications during 2025. Europe and North America collectively represented nearly 63% of global Lutetium-177 therapy demand.

Yttrium-90: Yttrium-90 accounted for approximately 14% market share during 2025 because liver cancer and lymphoma treatment procedures increased significantly. Around 37% of hepatic tumor embolization procedures integrated Yttrium-90 microsphere therapies due to improved localized radiation delivery performance. Hospitals expanded interventional oncology services during 2024, while approximately 28% of liver cancer treatment centers adopted advanced Yttrium-90 imaging guidance systems. Asia-Pacific demonstrated strong growth because liver cancer prevalence remained high across several countries. Automated radiation dosing technologies additionally improved treatment accuracy by 16%.

Samarium-153: Samarium-153 represented approximately 6% market share during 2025 because bone pain palliation therapies remained important for metastatic cancer management. Around 31% of advanced bone cancer patients receiving radionuclide treatment utilized Samarium-153 for pain reduction and improved mobility. Healthcare providers expanded palliative nuclear medicine programs during 2024 because metastatic skeletal complications increased globally. Approximately 24% of cancer hospitals integrated combined radionuclide and pain management protocols to improve patient quality of life. Europe represented nearly 29% of Samarium-153 therapy utilization because oncology palliative care infrastructure remained highly developed.

Strontium-89: Strontium-89 accounted for approximately 5% market share during 2025 because bone metastasis treatment procedures continued across oncology centers worldwide. Approximately 27% of metastatic skeletal cancer cases requiring radionuclide palliation involved Strontium-89 therapies due to effective bone pain management capabilities. North America and Europe collectively represented nearly 61% of Strontium-89 treatment demand because cancer pain management programs remained well established. Around 18% of nuclear medicine facilities upgraded radiation safety systems during 2025 for handling beta-emitting isotopes more efficiently.

Rhenium-188+Rhenium-186: Rhenium-188 and Rhenium-186 therapies represented approximately 4% market share during 2025 because targeted liver cancer and synovectomy procedures increased gradually. Around 19% of experimental radionuclide therapies under clinical evaluation integrated Rhenium isotopes due to favorable therapeutic radiation characteristics. Research institutions significantly contributed to market development, while approximately 33% of isotope therapy clinical trials during 2025 explored advanced Rhenium-based radiopharmaceutical applications. Asia-Pacific research centers increased isotope production investments by 14% to support therapeutic nuclear medicine innovation.

Erbium-169:  Erbium-169 accounted for approximately 3% market share during 2025 because radiation synovectomy procedures for inflammatory joint disorders remained specialized therapeutic applications. Around 22% of advanced rheumatoid arthritis radionuclide procedures utilized Erbium-169 because localized radiation reduced inflammation effectively. Europe represented nearly 41% of global Erbium-169 utilization because orthopedic nuclear medicine applications remained highly developed. Approximately 16% of nuclear medicine research institutes initiated studies involving advanced joint-targeted radionuclide therapies during 2024.

Phosphorous-32: Phosphorous-32 represented approximately 4% market share during 2025 because blood disorder and hematological treatment procedures continued in specialized oncology facilities. Around 28% of polycythemia vera radionuclide treatments involved Phosphorous-32 therapy due to effective bone marrow suppression capabilities. Hospitals and hematology institutes expanded radiation safety protocols during 2025, while approximately 19% upgraded isotope handling infrastructure for beta-emitting therapeutic materials. North America represented nearly 37% of global demand because hematological disorder treatment programs remained advanced.

Others: Other therapeutic isotopes, including Actinium-225 and Copper-67, accounted for approximately 3% market share during 2025 because targeted alpha therapy research accelerated globally. Around 31% of next-generation radionuclide therapy clinical trials involved emerging isotope technologies designed for precision oncology applications. Research investments expanded significantly, while approximately 27% of pharmaceutical development programs focused on advanced alpha-emitting therapeutic isotopes. North America and Europe collectively represented nearly 68% of experimental radionuclide therapy development activity during 2025.

BY APPLICATION

Hospitals: Hospitals dominated the therapeutic nuclear medicine market with approximately 63% market share during 2025 because large oncology centers performed high volumes of radionuclide therapy procedures. More than 52 million therapeutic nuclear medicine procedures were conducted globally, while approximately 61% occurred within hospital-based nuclear medicine departments. Hospitals expanded investment in AI-assisted treatment planning systems and automated isotope dispensing technologies during 2024. Around 43% of tertiary care hospitals upgraded radiation shielding infrastructure and radiopharmaceutical storage systems to improve operational efficiency and patient safety. North America and Europe represented the largest hospital-based therapeutic nuclear medicine markets.

Ambulatory Surgical Centers: Ambulatory surgical centers accounted for approximately 18% market share during 2025 because outpatient radionuclide therapies became increasingly common for thyroid disorders and targeted cancer treatment procedures. Around 36% of low-complexity radionuclide therapies shifted toward ambulatory care settings due to reduced patient hospitalization requirements. Treatment efficiency improvements increased patient throughput by 21% across specialized ambulatory nuclear medicine facilities during 2024. Approximately 27% of outpatient oncology clinics integrated compact isotope administration systems supporting same-day therapeutic procedures. Asia-Pacific demonstrated rising adoption of ambulatory therapeutic nuclear medicine infrastructure.

Cancer Research Institutes: Cancer research institutes represented approximately 19% market share during 2025 because radiopharmaceutical clinical trials and isotope therapy innovation programs expanded significantly. Around 47% of therapeutic nuclear medicine clinical studies focused on advanced targeted radionuclide therapies involving Lutetium-177 and alpha-emitting isotopes. Research institutes increased investment in isotope production facilities and radiopharmaceutical laboratories during 2025. Approximately 31% of oncology research centers integrated AI-supported molecular imaging systems to improve therapeutic targeting accuracy. Europe and North America remained dominant regions for therapeutic nuclear medicine research and clinical trial activity.

Therapeutic Nuclear Medicine Market Regional Outlook

Download FREE Sample to learn more about this report.

The therapeutic nuclear medicine market demonstrated strong regional expansion during 2025 because cancer incidence, radiopharmaceutical adoption, and isotope production investments increased worldwide. North America accounted for approximately 41% market share due to advanced oncology treatment infrastructure and domestic isotope manufacturing capacity. Europe represented nearly 29% share because theranostic medicine adoption accelerated significantly. Asia-Pacific captured approximately 24% market share because nuclear medicine infrastructure expanded across China, Japan, and India. The Middle East & Africa accounted for around 6% share because oncology care modernization and radiopharmaceutical imports increased steadily during 2025.

NORTH AMERICA

North America dominated the therapeutic nuclear medicine market with approximately 41% share during 2025 because oncology treatment infrastructure and radiopharmaceutical manufacturing capabilities remained highly advanced. The United States represented nearly 83% of regional market demand due to increasing cancer incidence and targeted radionuclide therapy adoption. More than 2 million new cancer cases were reported annually in the United States, while approximately 46% of oncology centers integrated advanced therapeutic nuclear medicine platforms during 2025. Lutetium-177 therapies demonstrated strong adoption because metastatic prostate cancer treatment demand increased significantly. Around 38% of nuclear medicine facilities upgraded automated isotope dispensing and AI-assisted dosimetry systems during 2024. Canada also expanded therapeutic isotope production infrastructure, while approximately 21% of radiopharmaceutical manufacturers increased domestic isotope supply capacity. Hospitals and ambulatory treatment centers across North America invested heavily in theranostic medicine programs. Around 33% of healthcare institutions launched integrated diagnostic and therapeutic radioligand treatment services during 2025. Research institutes further strengthened regional leadership. Approximately 47% of global therapeutic radiopharmaceutical clinical trials were conducted in North America during 2025 because regulatory approvals and oncology research funding remained favorable.

EUROPE

Europe accounted for approximately 29% market share during 2025 because therapeutic radiopharmaceutical adoption, cancer treatment modernization, and isotope research infrastructure expanded significantly. Germany, France, Italy, and the United Kingdom collectively represented nearly 68% of regional therapeutic nuclear medicine demand. Theranostic medicine emerged as a major growth driver across Europe. Around 44% of oncology treatment centers integrated combined diagnostic and therapeutic radionuclide programs during 2025. Lutetium-177 and Yttrium-90 therapies represented approximately 39% of therapeutic nuclear medicine procedures across the region because precision oncology approaches gained strong clinical acceptance.  Government-supported isotope production programs additionally strengthened regional supply chains. Approximately 26% of European radiopharmaceutical facilities upgraded cyclotron and reactor infrastructure during 2024 to improve isotope availability. Cancer research institutes also increased investments in alpha-emitting radionuclide therapies and AI-driven treatment planning systems. Hospitals across Europe expanded outpatient radionuclide treatment capabilities. Around 29% of ambulatory oncology centers integrated advanced radiation shielding systems and automated radiopharmaceutical preparation technologies during 2025 to support growing patient volumes.

ASIA-PACIFIC

Asia-Pacific represented approximately 24% market share during 2025 because healthcare infrastructure modernization and cancer treatment investments accelerated significantly. China, Japan, South Korea, and India collectively accounted for nearly 73% of regional therapeutic nuclear medicine procedures. Cancer prevalence remained a major growth factor across Asia-Pacific. More than 9 million new cancer cases were diagnosed annually across the region, while approximately 34% of tertiary oncology hospitals integrated advanced radionuclide therapy services during 2025. Iodine-131 therapies remained highly utilized because thyroid disorder prevalence increased steadily. Japan and South Korea led adoption of theranostic medicine technologies. Around 31% of oncology research centers across Asia-Pacific launched targeted radioligand therapy programs during 2024. China additionally expanded domestic isotope manufacturing capacity, while approximately 22% of nuclear medicine facilities upgraded isotope storage and handling systems. Government investments in healthcare digitization and precision oncology strengthened market expansion. Approximately 27% of hospitals across major Asia-Pacific economies integrated AI-supported molecular imaging systems during 2025 to improve therapeutic radiation targeting accuracy and treatment planning efficiency.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for approximately 6% of the global therapeutic nuclear medicine market during 2025 because oncology treatment infrastructure and radiopharmaceutical imports expanded steadily. Gulf countries represented nearly 57% of regional market demand because healthcare modernization initiatives accelerated significantly. Cancer treatment centers across the Gulf region increased therapeutic radionuclide procedure capacity during 2025. Around 28% of oncology hospitals integrated Lutetium-177 and Yttrium-90 therapy programs due to rising cancer incidence and medical tourism growth. Saudi Arabia and the United Arab Emirates expanded investments in advanced nuclear medicine facilities and radiation safety infrastructure. Research and academic institutions across the region increased focus on targeted radionuclide therapy education. Around 16% of nuclear medicine facilities launched specialized radiopharmacy training programs during 2025 to address workforce shortages and improve treatment quality standards.

List of Top Therapeutic Nuclear Medicine Companies

• Bayer AG
• GE Healthcare
• Novartis AG
• Cardinal Health Inc.
• Mallinckrodt plc.
• Lantheus Medical Imaging Inc.
• Bracco Imaging S.p.A
• Eckert & Ziegler
• Curium Pharma
• International Isotopes Idaho, Inc.
• Medi-Radiopharma Co., Ltd.

List of Top 2 Companies Market Share

• Novartis AG: accounted for approximately 24% market share during 2025 because Lutetium-177 radioligand therapy adoption expanded significantly across oncology treatment centers worldwide.
• Bayer AG: represented nearly 18% market share during 2025 due to strong Radium-223 therapeutic product adoption and global oncology distribution infrastructure.

Investment Analysis and Opportunities

Investments in the therapeutic nuclear medicine market increased substantially during 2025 because precision oncology, theranostic medicine, and targeted radiopharmaceutical therapies expanded rapidly. Approximately 44% of pharmaceutical manufacturers increased investment in isotope production and radiopharmaceutical research facilities during 2024. Therapeutic isotope manufacturing infrastructure became a major investment area. Around 26% of nuclear medicine companies upgraded cyclotron systems and isotope processing technologies during 2025 to improve Lutetium-177 and Yttrium-90 production capacity. Governments across North America and Europe additionally supported domestic isotope manufacturing initiatives to reduce supply chain dependency.

Cancer research institutes created strong investment opportunities because radioligand therapy clinical trials increased significantly. Approximately 47% of advanced oncology isotope studies focused on targeted alpha therapy and personalized radionuclide treatment approaches. Artificial intelligence integration and robotic radiopharmaceutical preparation systems also attracted substantial investment. Emerging economies presented additional opportunities because oncology infrastructure modernization accelerated. Around 31% of tertiary hospitals across Asia-Pacific and the Middle East expanded therapeutic nuclear medicine departments during 2025. Outpatient radionuclide therapy centers and ambulatory oncology clinics further contributed to investment growth across healthcare systems worldwide.

New Product Development

New product development in the therapeutic nuclear medicine market focused heavily on targeted alpha therapies, advanced theranostics, and AI-assisted treatment systems during 2025. Approximately 36% of radiopharmaceutical manufacturers launched development programs involving alpha-emitting isotopes such as Actinium-225 and next-generation Lutetium-based therapies.

Lutetium-177 radioligand products remained the leading innovation segment because metastatic prostate cancer and neuroendocrine tumor treatments expanded rapidly. Around 42% of newly developed therapeutic radiopharmaceuticals integrated precision tumor-targeting peptides during 2024. Treatment efficacy improvements additionally reduced healthy tissue exposure by nearly 18%. Manufacturers also focused on compact outpatient treatment solutions. Around 24% of new therapeutic nuclear medicine products launched during 2025 supported ambulatory radionuclide administration procedures. Enhanced radiation shielding materials and portable isotope delivery systems further improved treatment accessibility across smaller healthcare facilities.

Five Recent Developments

• In 2025, approximately 48% of advanced oncology treatment centers integrated theranostic radioligand therapy programs for metastatic cancer management.
• During 2024, Lutetium-177 treatment procedures increased by 34% globally because prostate cancer radionuclide therapy adoption accelerated significantly.
• In 2025, around 31% of radiopharmaceutical manufacturers expanded alpha-emitting isotope research and development programs targeting precision oncology applications.
• During 2024, approximately 26% of isotope production facilities upgraded cyclotron and reactor infrastructure to improve therapeutic isotope supply stability.
• In 2025, around 37% of nuclear medicine centers adopted AI-assisted treatment planning and automated dosimetry systems for improved therapy precision.

Report Coverage of Therapeutic Nuclear Medicine Market

The therapeutic nuclear medicine market report provides extensive analysis of radionuclide therapies, isotope production technologies, radiopharmaceutical applications, and regional oncology treatment infrastructure. The study evaluates therapeutic isotopes including Radium-223, Iodine-131, Lutetium-177, Yttrium-90, Samarium-153, Strontium-89, Rhenium isotopes, Erbium-169, and Phosphorous-32 used across oncology, hematology, cardiovascular, and palliative care applications.

The report includes segmentation analysis based on isotope type, healthcare application, and regional treatment adoption trends. Lutetium-177 accounted for approximately 29% market share during 2025 because targeted radioligand therapy demand expanded significantly. Hospitals represented nearly 63% of total therapeutic nuclear medicine utilization due to high patient volumes and advanced oncology treatment infrastructure. Regional analysis covers North America, Europe, Asia-Pacific, and the Middle East & Africa. North America dominated with approximately 41% market share because domestic isotope manufacturing and precision oncology programs remained highly advanced. Europe represented nearly 29% share because theranostic medicine adoption increased across cancer treatment centers.